- Home
- EXFY vs ACRS Comparison
EXFY vs ACRS Comparison
Compare EXFY & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXFY
- ACRS
- Stock Information
- Founded
- EXFY 2008
- ACRS 2012
- Country
- EXFY United States
- ACRS United States
- Employees
- EXFY N/A
- ACRS N/A
- Industry
- EXFY Computer Software: Prepackaged Software
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- EXFY Technology
- ACRS Health Care
- Exchange
- EXFY Nasdaq
- ACRS Nasdaq
- Market Cap
- EXFY 206.1M
- ACRS 165.7M
- IPO Year
- EXFY 2021
- ACRS 2015
- Fundamental
- Price
- EXFY $2.22
- ACRS $1.52
- Analyst Decision
- EXFY Strong Buy
- ACRS Strong Buy
- Analyst Count
- EXFY 3
- ACRS 9
- Target Price
- EXFY $4.75
- ACRS $9.25
- AVG Volume (30 Days)
- EXFY 1.1M
- ACRS 1.3M
- Earning Date
- EXFY 08-07-2025
- ACRS 08-06-2025
- Dividend Yield
- EXFY N/A
- ACRS N/A
- EPS Growth
- EXFY N/A
- ACRS N/A
- EPS
- EXFY N/A
- ACRS N/A
- Revenue
- EXFY $141,775,000.00
- ACRS $17,777,000.00
- Revenue This Year
- EXFY $7.77
- ACRS N/A
- Revenue Next Year
- EXFY $5.45
- ACRS $8.11
- P/E Ratio
- EXFY N/A
- ACRS N/A
- Revenue Growth
- EXFY N/A
- ACRS N/A
- 52 Week Low
- EXFY $1.45
- ACRS $1.05
- 52 Week High
- EXFY $4.13
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- EXFY 38.30
- ACRS 53.10
- Support Level
- EXFY $2.14
- ACRS $1.54
- Resistance Level
- EXFY $2.61
- ACRS $1.68
- Average True Range (ATR)
- EXFY 0.13
- ACRS 0.10
- MACD
- EXFY -0.03
- ACRS 0.01
- Stochastic Oscillator
- EXFY 8.63
- ACRS 46.82
About EXFY Expensify Inc.
Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.